Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0243 GMT – Breathing-tech provider ResMed doesn’t get enough ...

The Trump administration has put a freeze on many federal health agency communications with the public through at least the ...

The Trump administration has put a freeze on many federal health agency communications with the public through at least the ...

Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

To address these shortages, the FDA has put measures into place, including expedited review processes and the use of enforcement discretion. The FDA also now requires manufacturers to give at least ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.